Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)
121 Downloads (Pure)

Abstract

For a long time, metformin has been the first-line treatment for glycemic control in type 2 diabetes; however, the results of recent cardiovascular outcome trials of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists have caused many to question metformin’s position in the guidelines. Although there are several plausible mechanisms by which metformin might have beneficial cardiovascular effects, for example, its anti-inflammatory effects and metabolic properties, and numerous observational data suggesting improved cardiovascular outcomes with metformin use, the main randomized clinical trial data for metformin was published over 20 years ago. Nevertheless, the overwhelming majority of participants in contemporary type 2 diabetes trials were prescribed metformin.
Original languageEnglish
Pages (from-to)291-299
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume32
Issue number4
Early online date27 Mar 2023
DOIs
Publication statusPublished - 2023

Keywords

  • cardiovascular disease
  • diabetes
  • heart failure
  • metformin
  • inflammation
  • Cardiovascular disease

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease'. Together they form a unique fingerprint.

Cite this